Search

Search Results

• 

  OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart¹, M.E. Burczynski¹, P. Banerjee¹, M. Onisko¹, Y. Wang¹, K. Mohammadi¹, D. Li¹, S. Li¹, J. Ackroyd², B.A. Olenchock¹, D.E. Gutstein¹, J. I. Weitz³ | ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; ²Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; ³McMaster University, Hamilton, ON, Canada

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.492

  102

  PDF: 36
• 

  PO52 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC AND TIME-TO-EVENT MODELING SUPPORT SUSTAINED FACTOR XI INHIBITION AND SUPERIOR POST-OPERATIVE VENOUS THROMBOEMBOLISM PREVENTION WITH REGN7508^CAT O. Milberg¹, H. Abdallah¹, R.K. Lokken², R. Dingman¹, K.A. Meagher¹, P. Banerjee¹, M.E. Burczynski¹, E. Marin¹, A.P. Kithcart¹, D.E. Gutstein¹ | ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; ²Allucent, Cary, NC, USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.544

  101

  PDF: 24
• 

  PO51 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF FACTOR XI-TARGETING MONOCLONAL ANTIBODIES SUPPORTS DURABLE ANTICOAGULANT COVERAGE AND TRANSLATIONAL DOSE AND REGIMEN SELECTION O. Milberg¹, H. Abdallah¹, R.K. Lokken², R. Dingman¹, K.A. Meagher¹, M.E. Burczynski¹, E. Marin¹, A.P. Kithcart¹, D. E. Gutstein¹ | ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; ²Allucent, Cary, NC, USA

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.543

  109

  PDF: 24